Bio-Techne

Spear Bio is a biotechnology company established in 2021 and located in Weston, Massachusetts. The company specializes in ultrasensitive protein detection technology, which provides significant advantages in the healthcare sector. Its innovations support self-testing and telemedicine-based diagnostics by enabling the quantification of minute protein biomarkers from samples collected at home. This approach allows clinicians to achieve ultrasensitive detection using small sample volumes, seamlessly integrating into existing workflows for sample collection, processing, and analysis.

Lunaphore specializes in tumor analysis through innovative microfluidic chip technology, which allows for rapid and precise assays that surpass traditional methods. The company's platform facilitates the extraction of spatial proteomic and transcriptome data from tumors and other tissues, transforming standard assays into multiplex spatial biology with a user-friendly interface. This technology aids researchers in immunology, immuno-oncology, and neurology by identifying clinically relevant biomarker signatures, which support the development of diagnostic tools and streamline clinical trials. By improving the efficiency of cancer diagnostics and enhancing the accuracy of results, Lunaphore ultimately aims to contribute to better patient outcomes.

Wilson Wolf Corporation, founded in 1998, specializes in the design and manufacture of innovative cell culture devices aimed at advancing healthcare solutions. The company develops a range of products for diverse applications such as monoclonal antibody production, living skin, corneal storage, islet transplants for type 1 diabetes, and immunotherapy. Their revolutionary gas permeable cell culture device platform serves as an alternative to traditional methods like plates, flasks, and bags, providing enhanced options for scientists and businesses engaged in cell culture. Wilson Wolf is committed to contributing to medical advancements, particularly in cancer treatment and regenerative medicine.

Namocell Inc. is a biotechnology firm based in Mountain View, California, that specializes in the development, manufacture, and distribution of microfluidic-based platforms for single-cell enrichment, sorting, and analysis. Founded in 2014, the company focuses on applications in life science research and clinical settings, including cell line development, cancer diagnostics, and immunotherapy. Namocell's innovative single-cell dispensers enable researchers to efficiently identify and isolate individual cells while maintaining their viability and integrity. Their technology serves a diverse range of applications, such as CRISPR and induced pluripotent stem cell cloning, single-cell genomics, cell and gene therapy, antibody discovery, rare cell isolation, and synthetic biology.

Asuragen, Inc. is a molecular diagnostics company based in Austin, Texas, focused on providing patient management solutions for oncology and genetic disorders. Founded in 2005, Asuragen develops and commercializes diagnostic products for clinical laboratories and biopharma partners. Its product portfolio includes the AmplideX FMR1 PCR reagents for detecting CGG repeats in the fragile X mental retardation gene, various cancer testing kits like QUANTIDEX, and the Signature technology for multiplex analysis of nucleic acid sequences, which includes assays for mutations in KRAS and BRAF genes. In addition to these diagnostic tools, Asuragen offers GLP testing services, cGMP manufacturing capabilities, and expertise in biomarker discovery and regulatory processes. This integrated approach facilitates the development, testing, and commercialization of diagnostic solutions aimed at improving treatment outcomes in oncology and genetic conditions.

Eminence specializes in the development and manufacturing of chemically-defined media for cell culture, particularly focusing on CHO (Chinese Hamster Ovary) cells. The company has created proprietary products such as EmCD CHO® basal medium and EmCD CHO® Feed, which are designed for various CHO cell lines, including CHO-K1, CHO-S, and CHO-DG44. Eminence offers a comprehensive range of services, including medium formulation development and optimization, tailored to meet the specific needs of its clients in the biopharma sector. With a skilled research and development team and GMP-compliant production facilities, Eminence is committed to delivering high-quality products and flexible solutions, supporting biopharmaceutical companies in adhering to stringent safety and efficacy standards in their processes.

B-MoGen Biotechnologies, based in Saint Paul, Minnesota, specializes in gene editing solutions for various applications, including antibody validation, human disease research, and mitochondrial DNA editing. The company offers a range of services, such as custom vector generation, which includes multi-gene expression vectors delivered via the sleeping beauty transposon system, and custom gene targeting vectors. Additionally, B-MoGen provides genome modification services, including gene knockout, gene knock-in, and the generation of stable transposon cell lines. Their products, including sleeping beauty transposon and transposase vectors, are available for purchase through Neuromics. Since its founding in 2015, B-MoGen has established strategic partnerships with biotechnology firms and completed projects across academia and industry while developing novel intellectual property in the field of genome engineering.

Exosome Diagnostics, Inc. specializes in the development and commercialization of biofluid-based molecular diagnostic tests aimed at enhancing personalized precision healthcare. The company employs a proprietary exosome technology platform that extracts and analyzes molecular information from exosomes present in various biofluids, including blood, urine, and cerebrospinal fluid. This approach enables non-invasive diagnostics for serious diseases, significantly reducing the need for tissue biopsies. One of its key products is the MedOncAlyzer 170, a liquid biopsy pan-cancer panel that simultaneously analyzes exosomal RNA and circulating tumor DNA in a single assay to identify actionable mutations across multiple cancer types. By combining RNA, DNA, and protein analysis, Exosome Diagnostics provides comprehensive molecular insights that can transform the detection, diagnosis, treatment, and monitoring of cancer and other serious conditions. The company also collaborates with pharmaceutical firms to enhance research and development processes, including biomarker discovery and the creation of companion diagnostics. Founded in 2008 and based in Cambridge, Massachusetts, Exosome Diagnostics operates as a subsidiary of Bio-Techne Corporation.

Quad Technologies is disrupting cell separation and cell therapy workflows by providing researchers with a simple, cell-friendly capture and release technology for cell isolation. Their new MagCloudz™ Streptavidin Cell Separation kit, featuring novel QuickGel™ technology platform, enables straightforward, scalable and fast cell separation with unique magnetic particle dissociation, resulting in complete label free cells. For applications such as T Cell purification, stem cell isolation, circulating tumor cell (CTC) separation and immunotherapy, this unique solution offers drastically improved cell viability, purity and recovery while maintaining a native cellular phenotype.

Astute Medical, Inc. is a life science tools company specializing in the discovery and development of protein biomarkers for rapid diagnosis and risk assessment of acute medical conditions. Founded in 2007 and based in San Diego, California, with a location in Paris, France, the company focuses on validating prognostic biomarkers related to conditions such as abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury, and sepsis. Its primary product, NephroCheck, is a single-use cartridge designed to detect biomarkers of acute kidney injury, while the Astute140 meter converts the fluorescent signals from the NephroCheck cartridge into a single numerical result. Astute Medical's products are marketed in the United States and Europe and aim to enhance clinical decision-making and patient outcomes. As of April 2018, Astute Medical operates as a subsidiary of bioMérieux S.A.

Advanced Cell Diagnostics, Inc. specializes in developing and commercializing cell and tissue-based diagnostic tests aimed at enhancing personalized medicine. Utilizing its proprietary RNAscope technology, the company offers a versatile platform for multiplex fluorescent and chromogenic in situ hybridization, allowing for the detection and quantification of RNA biomarkers with single molecule sensitivity. Its product portfolio includes manual assays, reagent kits in various formats, and software tools for quantitative analysis of RNA in situ hybridization samples. The company serves pharmaceutical and biotech sectors by providing assay services that facilitate understanding of disease mechanisms and support various stages of clinical trials. Additionally, Advanced Cell Diagnostics maintains a companion diagnostic assay development program to streamline assay processes. The company's products are distributed across numerous countries and are also available for purchase online. Founded in 2007 and located in Hayward, California, Advanced Cell Diagnostics operates as a subsidiary of Bio-Techne Corp.

Space Import Export S.r.l. is a distribution company that has been working in the Life Science business since 1985, specialized in the fields of Biomedical Research and Diagnostic Market. Our distribution activity has grown, through an active cooperation with a sister company, called LaboSpace, provider of laboratory services, with branches in Italy, UK and USA.

Zephyrus Biosciences, Inc. is a life science research tools company based in Berkeley, California, founded in 2013. The company specializes in the development and commercialization of innovative research tools that facilitate protein analysis at the single-cell level. Its flagship product, the scWestern System, allows for western blotting on individual cells, a significant advancement in the field of single-cell analysis. This system employs microfluidics technology to isolate single cells in micro-wells, lysing them and performing SDS-PAGE separation on each lysate. Researchers utilize Zephyrus's tools to explore critical areas such as cancer biology, stem cell research, neurology, and broader human disease studies, ultimately contributing to advancements in diagnostics and therapeutics. As of March 2016, Zephyrus operates as a subsidiary of Bio-Techne Corp.

CLINIQA Corp specializes in the manufacturing and commercialization of quality controls and calibrators for the in vitro diagnostics (IVD) industry. With over 40 years of experience, the company has established a reputation for producing high-quality products that enhance the accuracy of diagnostic tests. CLINIQA operates from facilities in San Diego County, California, and adheres to stringent quality management systems that comply with FDA regulations and international standards. The company offers a range of products, including reagents, controls, calibrators, proficiency test materials, and contract manufacturing services. Notably, its Liquid QC® products provide "ready-to-use" solutions with extended shelf life and stability, addressing market demands for convenience and reproducibility. CLINIQA's commitment to quality and focus on liquid stabilization technology underpins its success in meeting the needs of the diagnostic sector.

CyVek, Inc. is a biotechnology company based in Wallingford, Connecticut, established in 2008. The company specializes in developing a technology platform designed for measuring analytes in biological samples. CyVek offers an integrated test system that features a microfluidic cartridge, enabling the analysis of multiple biomarkers from minimal quantities of biological materials. This innovative approach facilitates efficient and accurate testing, supporting advancements in diagnostics and research.

Novus Biologicals, LLC is dedicated to accelerating scientific discovery by developing and marketing specialized products for the life sciences sector. The company offers a wide range of research tools, including primary and secondary antibodies, peptides, proteins, kits, controls, lysates, RNAi, and other reagents essential for life science research. These products aid in the study of protein functions across various fields, such as cancer, neuroscience, autophagy, and cardiovascular research. Novus Biologicals focuses on monitoring scientific trends to ensure the availability of relevant materials and provides detailed technical information and ongoing support to researchers. By catering to both niche and emerging markets, Novus Biologicals fosters strong partnerships with its customers, ultimately contributing to the advancement of biological research.

ProteinSimple is a prominent company within the Protein Platforms division of Bio-Techne, specializing in innovative solutions for protein analysis. The company develops a comprehensive range of tools designed to assist life science researchers in addressing complex protein analysis challenges, thereby facilitating insights into proteins and their roles in diseases. Its product offerings include advanced immunoassay systems for quantifying protein expression and sophisticated systems for assessing the structure and purity of protein-based therapeutics. Additionally, ProteinSimple provides nano-proteomic analysis systems that enable researchers to measure phospho-protein signaling and activation in small biological samples, allowing for the quantification of phospho-protein isoforms in various cell types. Through these capabilities, ProteinSimple supports critical research in understanding cellular processes and monitoring drug actions in diverse biological contexts.

Shanghai PrimeGene Bio-Tech Co is a prominent company based in Shanghai, China, specializing in the development, manufacture, and distribution of recombinant proteins for research and diagnostic applications. The company provides a wide array of high-quality recombinant proteins and associated antibodies tailored for bio-reagent companies. Its product offerings include recombinant proteins, recombinant antigens for diagnostics, protein A, protein G, protein L, monoclonal antibodies, protein standard markers, and services related to gene cloning, synthesizing, and gene expression in E. coli and yeast systems. Through its focus on quality and innovation, Shanghai PrimeGene Bio-Tech Co plays a significant role in advancing diagnostic research in the biotechnology sector.

CyVek, Inc. is a biotechnology company based in Wallingford, Connecticut, established in 2008. The company specializes in developing a technology platform designed for measuring analytes in biological samples. CyVek offers an integrated test system that features a microfluidic cartridge, enabling the analysis of multiple biomarkers from minimal quantities of biological materials. This innovative approach facilitates efficient and accurate testing, supporting advancements in diagnostics and research.

Bionostics is a world-leading developer and manufacturer of high quality, turnkey calibrators and quality control products for original equipment manufacturers (OEMs) for critical care / point-of-care and diabetes diagnostics test systems. Located in Devens, Massachusetts, Bionostics offers a variety of services to provide high quality, cost effective, turn-key solutions to our customers, large and small. We maintain professional associations with customers and suppliers, striving to work together in relationships that are beneficial for all parties. As a key partner to world-class OEMs, we are acutely aware of our responsibility to maintain and foster the brand identities of our clients. Our quality systems are certified to ISO 9001:2008 and 13485:2003. Our products are listed as Class I and Class II with the US FDA, bear Class II and Class III Medical Device Licenses in Canada and fully comply with requirements of 98/79/EC, the In-Vitro Diagnostics Directive.

Tocris Holdings is a supplier of reagents for non-clinical life science research.

ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company based in Mountain View, California, focused on developing and commercializing innovative medications for inflammatory disorders, autoimmune diseases, and cancer. The company's lead drug candidate, Avacopan, is an orally-administered complement inhibitor currently undergoing Phase III trials for anti-neutrophil cytoplasmic auto-antibody-associated vasculitis and a Phase IIb trial for moderate-to-severe hidradenitis suppurativa and complement 3 glomerulopathy. Additionally, ChemoCentryx is advancing other drug candidates, including CCX140, an inhibitor targeting the CCR2 chemokine receptor, which has completed Phase II trials for diabetic nephropathy and is being developed for focal segmental glomerulosclerosis; CCX507, a second-generation CCR9 inhibitor that has completed Phase I trials; and CCX872, a selective CCR2 inhibitor currently in Phase Ib trials for stage 3 and 4 pancreatic cancer. ChemoCentryx aims to address the underlying immune system dysfunction associated with various conditions through its targeted therapeutics.